August 26, 2014
PeptiDream Inc
http://www.peptidream.com/
(Ticker Code：4587 TSE Mothers)

Carl Decicco, Senior Vice President & Head of Discovery, Research & Development at Bristol Myers Squibb, Presented Findings on the PeptiDream Collaboration at the 248th American Chemical Society National Meeting and Exposition in San Francisco, CA – August 10-14th, 2014

TOKYO, JAPAN – August 26, 2014 – PeptiDream Inc, a Tokyo-based biopharmaceutical company ("PeptiDream") announced today that Dr. Carl Decicco, Senior Vice President and Head of Discovery, Research & Development, at Bristol Myers Squibb (BMS) presented work from the PeptiDream - BMS collaboration project in an oral session entitled "Accessing therapeutically important proteins with millamolecules" under the Session Program "New Approaches To Difficult-To-Drug Targets and Diseases", at the 248th ACS (American Chemical Society) National Meeting and Exposition, August 10-14, 2014, San Francisco, CA.

Millamolecules is a term coined by BMS referring to constrained peptides in the 500-2000Da size space. Dr. Decicco presented on one of the lead programs between PeptiDream and BMS, and discussed the power of PeptiDream's PDPS technology to identify novel therapeutically relevant constrained peptides (millamolecules), and the potential for using these constrained peptides to therapeutically target difficult to drug targets.

Oral Session Abstract; "*The discovery of promising new compounds for difficult to drug, therapeutically relevant proteins will be highlighted. A powerful example of the use of chemical genetics screening which led to the elucidation of a new class of rule-breaker drug candidates will be described. The creation of highly diverse millamolecule libraries have led to the discovery of important new molecules that are active against non-traditional targets. The discovery, the advancement of these molecules and their significance as new therapeutic agents will be discussed.*"

Link
http://abstracts.acs.org/chem/248nm/program/view.php?obj_id=265816&terms=

<About PeptiDream Inc.>
PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit http://www.peptidream.com/en/

Enquiries:
PeptiDream Inc.
Patrick C Reid +81-3-5790-9991 (Tokyo)
EMAIL: p-reid@peptidream.com